Showing results (391-400 of 6,286) with videos related to

Sort By:
Pageof 629
Diabetes, Obesity & Metabolism|April 19, 2017
Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetesAnders Gummesson, Elisabeth Nyman, Mikael Knutsson, et al.
Diabetes, Obesity & Metabolism|April 23, 2017
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitorRalph A DeFronzo
Diabetes, Obesity & Metabolism|April 23, 2017
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponentsMelanie J Davies, Lawrence A Leiter, Bruno Guerci, et al.
Diabetes, Obesity & Metabolism|November 19, 2016
Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetesDavid Preiss, Adem Dawed, Paul Welsh, et al.
Diabetes, Obesity & Metabolism|November 19, 2016
Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival dataSteve Bain, Eric Druyts, Chakrapani Balijepalli, et al.
Diabetes, Obesity & Metabolism|November 19, 2016
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trialsKarolin Bettge, Melanie Kahle, Mirna S Abd El Aziz, et al.
Diabetes, Obesity & Metabolism|November 19, 2016
A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapiesWenhui Wei, Erin Buysman, Michael Grabner, et al.
Diabetes, Obesity & Metabolism|November 3, 2016
Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetesStéphanie Laugier-Robiolle, Bruno Vergès, Maëlle Le Bras, et al.
Diabetes, Obesity & Metabolism|October 8, 2016
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patientsMirna S Abd El Aziz, Melanie Kahle, Juris J Meier, et al.
Diabetes, Obesity & Metabolism|October 11, 2016
Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential actionS J Jacober, M J Prince, J M Beals, et al.
Pageof 629